Gerosa M, DiStefano E, Carli M, Iraci G
Childs Brain. 1980;6(5):262-73.
29 out of 34 consecutive patients of pediatric age, operated upon for posterior fossa medulloblastoma, were divided into 2 groups according to the chemotherapeutic treatment (intrathecal methotrexate or intravenous cyclophosphamide) received at random after surgery and radiation treatment. The modalities of irradiation and chemotherapy are described. 9 patients have not yet shown a local recurrence and are alive at varous intervals after surgery. Only 1 patient with local recurrence is still alive 31 months after the primary operation. The mean actuarial survival of the whole series of patients is about 38 months. Differences between the two groups, concerning either the survival rate till local recurrence, or the general and neurologic conditions of survival, are not statistically significant. Hematologic toxicity was more pronounced in the group treated with cyclophosphamide, whereas late neurologic sequelae were a more prominent feature of the intrathecal methotrexate trial.
34例接受后颅窝髓母细胞瘤手术的连续儿科患者中，29例根据术后和放疗后随机接受的化疗治疗（鞘内注射甲氨蝶呤或静脉注射环磷酰胺）分为2组。描述了放疗和化疗的方式。9例患者尚未出现局部复发，术后在不同时间间隔存活。只有1例局部复发患者在初次手术后31个月仍存活。整个系列患者的平均精算生存率约为38个月。两组之间在局部复发前的生存率、总体生存状况和神经状况方面的差异无统计学意义。环磷酰胺治疗组的血液学毒性更明显，而鞘内注射甲氨蝶呤试验中晚期神经后遗症是更突出的特征。
